News

These results were confirmed both in vitro as well as in vivo brain tumor models, the company said. These new results have demonstrated that the compound that Oncolin

The letter indicated that the application may be approved if the company is able to adequately respond to certain clinical deficiencies related to the product. The FDA has

The company’s first product, the inReach System, provides minimally invasive electromagnetic navigation (similar to GPS) to distant regions of the lungs, enabling doctors to diagnose lung cancer at

Bavarian Nordic claims that the defendants have infringed its three patents by commercializing the patented technology in ways that have yielded large payments from Sanofi-Aventis under the agreement

The granting of this patent is expected to provide protection in the US as well as in major markets internationally. Russell Mitchell, CEO of PuraMed Bioscience, said: “The

The University of Missouri (MU) holds intellectual property for a system than can generate clinically relevant quantities of radioisotopes (including Mo-99), the production of which normally requires a

The parties have agreed to jointly move to dismiss the underlying arbitration action and all related claims and counterclaims, with prejudice. In addition, in connection with dismissing the

Par’s dronabinol is approved to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments and is available

Acusphere’s Imagify is an ultrasound imaging agent for the detection of coronary artery disease. The new drug application (NDA) includes data from studies of Imagify in more than